Incannex Healthcare has transitioned its IHL-42X drug candidate from regulatory preparation to active clinical trials, enrolling about 120 patients across nine dose combinations at 14 U.S. sites. The study aims to optimize dosing ahead of a planned Phase 3 trial expected to start after mid-2027. The company has $68.4 million in cash, supporting at least 12 months of operations, but will need more funding for later stages. The focus is now on IHL-42X and its progression to Phase 3, while other pipeline projects face challenges or termination.
Incannex Healthcare's drug development progress is shared here with a snapshot of the health sector on Pluang. As of Oct 01, 2026 20:52 WIB, 30 of 100 priced health-sector US stocks rose while 67 fell. Notable movers include TLRY at USD 3.61 with a 1-day change of -3.73%, CTXR at USD 0.55 up 3.58%, and HIMS at USD 29.00 down 2.65%.
Beneficient is set to report its Q3 2026 earnings on October 5, with analysts expecting $0.97 EPS and $13.1 million in revenue. The company is involved in disputes over allegedly fraudulent debt and equity claims linked to HCLP Nominees and former CE...
Robinhood Markets is broadening its platform with new features like AI-powered Robinhood Agents, crypto perpetual futures, earnings contracts, and social investing tools. The company plans to offer 24/7 trading for select U.S. stocks and ETFs, plus e...
American Battery Technology Company secured a $100 million export license from the U.S. Department of Commerce to sell recycled battery black mass, which contains critical minerals like lithium and cobalt. The company is expanding its recycling opera...
Cal-Maine Foods reported a fiscal Q1 loss of $1.26 per share, wider than the expected loss of $0.77, with revenue falling to $539.6 million, below estimates. The 42% year-over-year sales decline was driven by lower egg prices, significantly impacting...
An analyst at Truist Financial raised Wells Fargo's price target to $95, suggesting a 20.74% upside from its current price. This optimism is driven by expected strong third-quarter earnings of $1.85 per share and $22.34 billion in revenue, surpassing...
